Hendrik van Dullemen

Zoekresultaten

• 2016

  In a Dutch real-life inflammatory bowel disease score cohort with 90% prior anti-tumour necrosis factor failure, vedolizumab showed a 25% remission rate: a retrospective multicentre study

  Gabriëls, R. Y., de Graaf, A. P. J., Meijssen, M. A. C., Gotz, J., Mensink, P., Russel, M., van Dullemen, H., ter Steege, R. W. F., Weersma, R. & Dijkstra, G., 2016.

  Onderzoeksoutput › Academic

  • Inflammatory Bowel Disease 100%
  • Spontaneous Remission 100%
  • Tumor Necrosis 100%
  • Vedolizumab 100%
  • Crohn's Disease 70%

• The value of endoscopic ultrasonography in a PET/CT upfront model in staging esophageal cancer with respect to treatment decision

  Hulshoff, J.-B., de Boer, H., Noordzij, W., Nagengast, W., van Dullemen, H., Mul, V. & Plukker, J. T. H. M., 2016.

  Onderzoeksoutput: Abstract › Academic